The risk of SARS-CoV-2 outbreaks in low prevalence settings following the

removal of travel restrictions

AUTHORS

R. Sachak-Patwa[1], H.M. Byrne[1], L. Dyson[2,3], R.N. Thompson[2,3,*]

*Correspondence to: robin.n.thompson@warwick.ac.uk

AFFILIATIONS

[1]Mathematical Institute, University of Oxford, Oxford, UK

[2]Mathematics Institute, University of Warwick, Coventry, UK

[3]Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research,

University of Warwick, Coventry, UK

ABSTRACT

Countries around the world have introduced travel restrictions to reduce SARS-CoV-2

transmission. As vaccines are gradually rolled out, attention has turned to when travel

restrictions and other non-pharmaceutical interventions (NPIs) can be relaxed. Here,

using SARS-CoV-2 as a case study, we develop a mathematical branching process

model to assess the risk that, following the removal of NPIs, cases introduced into new

locations initiate a local outbreak. Our model accounts for changes in background

population immunity due to vaccination. We consider two locations in which the vaccine

rollout has progressed quickly – specifically, the Isle of Man (a British crown

dependency in the Irish Sea) and the country of Israel. We show that the outbreak risk

is unlikely to be eliminated completely when travel restrictions and other NPIs are

removed, even once the vaccine programmes in these locations are complete.

Specifically, the risk that an imported case initiates an outbreak following the vaccine

rollout and removal of NPIs is projected to be 0.373 (0.223,0.477) for the Isle of Man

and 0.506 (0.387,0.588) for Israel. Key factors underlying these risks are the potential

for transmission even following vaccination, incomplete vaccine uptake, and the recent

emergence of SARS-CoV-2 variants with increased transmissibility. Combined, these

factors suggest that when travel restrictions are relaxed, it will still be necessary to

implement surveillance of incoming passengers to identify infected individuals quickly.

This measure, as well as tracing and isolating contacts of detected infected passengers,

should remain in place to suppress potential outbreaks until case numbers globally are

reduced.

KEYWORDS

mathematical   modelling;   infectious   disease   epidemiology;   outbreaks;   non-

pharmaceutical interventions; travel restrictions

42   1. INTRODUCTION

Combinations of non-pharmaceutical interventions (NPIs) have been introduced

worldwide to counter the COVID-19 pandemic [1–3]. These measures include travel

restrictions [4,5] and a range of other NPIs intended to reduce the numbers of contacts

between individuals [6]. The development and deployment of vaccines has also lowered

transmission [7–10] and reduced the number of individuals experiencing clinical

symptoms or severe disease once infected [11–13].

Effective NPIs have led to low levels of transmission in some locations. Australia and

New Zealand have often been cited as examples of countries that have implemented

NPIs effectively, with travel restrictions and quarantine of inbound travellers combined

with short-term lockdowns and contact tracing to identify infected contacts whenever

cases have been discovered [14–16]. At the time of writing (1st May 2021), Israel is the

country that has vaccinated the largest proportion of its citizens, and the vaccination

campaign there has been credited with reducing transmission [8], prompting some NPIs

to be removed.

Despite the success of both NPIs and vaccines, the current overall picture is

complicated. Vaccines do not prevent transmission entirely [7,17,18], and vaccine

uptake is incomplete, particularly in some ethnic groups and in underserved

communities [19]. Current tentative estimates suggest that first doses of the Pfizer and

AstraZeneca SARS-CoV-2 vaccines are around 60% effective at preventing infection,

with the second doses leading to 65-85% efficacy against infection [17]. Furthermore,

the appearance of novel SARS-CoV-2 variants makes eliminating transmission more

challenging. For example, the B.1.1.7 variant (VOC 202012/01) that first appeared in

the United Kingdom in late 2020 has been found to be more transmissible than the

SARS-CoV-2 virus that originally emerged in China [20]. Although public health

measures have had some successes, these concerns raise a key question: Can NPIs

such as travel restrictions be removed without any risk in low prevalence settings where

vaccines have been distributed widely, or might outbreaks occur initiated by SARS-

CoV-2 reimportations from elsewhere?

Epidemiological models are often used to assess the risk of outbreaks in scenarios in

which the potential for pathogen transmission is not changing. According to the

mathematical theory of branching processes, the probability that cases introduced into a

new host population generate an outbreak driven by sustained local transmission is

given by

$$\text{Prob(outbreak)} = 1 - \left(\frac{1}{R}\right)^{I_0}, \qquad (1)$$

in which R is the reproduction number of the pathogen and I_0 is the number of

introduced infectious cases. This expression had been used to assess the risks of

outbreaks of pathogen including the Ebola virus [21–23], before being applied early in

the COVID-19 pandemic to assess outbreak risks outside China [24]. Equation (1)

reflects the risk that introduced cases generate an outbreak, however it involves an

assumption that pathogen transmissibility is fixed at its current level. In other words, the

value of R is implicitly assumed to remain constant over the initial phase of the potential

outbreak. With a background of rapidly changing population immunity due to vaccination

acting to reduce transmission, this assumption may not be accurate. To assess the risk

of outbreaks if NPIs are removed during an ongoing vaccination campaign using

branching process models, standard epidemiological modelling theory must be

extended to account for temporally changing population immunity.

Here, we use branching processes to investigate whether or not an introduced case

initiates an outbreak, accounting fully for temporal changes in population immunity due

to an ongoing vaccination campaign. We use four metrics to assess the risk of an

outbreak and consider two examples of vaccination campaigns from around the world,

from the Isle of Man and the country of Israel. In both locations, vaccination is

progressing quickly and prevalence is currently low. Given the relatively low numbers of

cases in these locations during the pandemic, there is also likely to be a background of

limited immunity from previous infections. We assess the risk of outbreaks in these

places when travel restrictions and other NPIs are removed, considering scenarios in

which NPIs are removed at different stages of the vaccination campaigns. Crucially,

even when all vaccines have been deployed in those locations, we project that the

combination of incomplete vaccine uptake, imperfect vaccination and variants of

concern mean that the risk of outbreaks due to imported cases will not be eliminated

completely when NPIs are removed. This highlights the need for careful monitoring of

imported cases until global prevalence is reduced to low levels. Until vaccines are rolled

out worldwide, there is still a risk of local transmission arising in low prevalence settings

initiated by importations from elsewhere.

112   **2. METHODS**

Epidemiological model

We performed our analyses using a stochastic branching process model that describes

virus transmission in the initial stages of a potential outbreak. In the model, following the

arrival of a case in the local population, new infections occur at rate $\beta(1 - \Lambda(t))$ and

infected individuals have a mean infectious period of $1/\mu$ days (Fig 1a). The function

$\Lambda(t)$ reflects the extent to which transmission has been reduced by vaccination, where a

value of $\Lambda(t) = 0$ corresponds to an entirely unvaccinated population.

To model an ongoing vaccination campaign, we set $\Lambda(t) = \eta_1 V_1(t - \alpha) + \eta_2 V_2(t - \alpha)$,

where $V_1(t)$ is the proportion of individuals in the population who have received a single

vaccine dose at time t and $V_2(t)$ is the proportion of individuals in the population who

have received two vaccine doses at time t (Fig 1b). The parameters η_1 and η_2 reflect

the effectiveness of the vaccine at preventing infection after one and two effective

doses, respectively (specifically, η_1 and η_2 represent the multiplicative reduction in

susceptibility following one or two effective doses, compared to an unvaccinated

individual, so that $0 \leq \eta_1 \leq \eta_2 \leq 1$), and the parameter α represents the delay between

a vaccine dose being administered and being effective in the recipient. In our main

analyses, since we are modelling relatively low prevalence settings, we do not consider

immunity due to prior infections, although we present a supplementary analysis in which

we considered the robustness of our results to this assumption.

Under this model, the time-dependent reproduction number, accounting for any

vaccines that have been administered and are effective at time t, is given by

138
$$R_V(t) = \frac{\beta(1 - \Lambda(t))}{\mu}. \qquad (2)$$

The value of $R_V(t)$ represents the expected number of secondary infections generated

by a single infected individual in the population at time t, under the assumption that no

further vaccinations take place in future. It is therefore representative of the

"instantaneous" transmissibility at time t. Indeed, $R_V(t)$ is sometimes referred to as the

instantaneous reproduction number [25–27]. In the absence of vaccination, so that $\Lambda(t) =$

0, then $R_V(t)$ is equal to the basic reproduction number, R_0.

(a) Transmission model

(b) Vaccination

Figure 1. The epidemiological model used in our analysis. (a) Following the introduction of an infected

individual into the host population, local transmission may happen with infections occurring at rate $\beta(1 -$

$\Lambda(t))$, where $\Lambda(t)$ reflects the vaccination coverage in the local population. Infected individuals have mean

infectious period $1/\mu$ days. (b) The vaccination process is modelled by setting $\Lambda(t)$ according to the

proportion of individuals in the population who have been vaccinated with one (V_1) or two (V_2) doses. The

first vaccine dose is assumed to have effectiveness η_1 and the second vaccine dose has effectiveness η_2,

where the values of η_1 and η_2 are the multiplicative reductions in the susceptibility of individuals who have

been vaccinated with one or two vaccine doses, respectively (compared to an unvaccinated host).

Vaccine doses are effective α days after they are administered. This leads to declining population

susceptibility as a vaccine is rolled out across the population.

<u>Vaccination data</u>

In the model, $V_1(t)$ and $V_2(t)$ were set based on vaccination data from the location

under consideration (either the Isle of Man or Israel). Data describing the proportion of

the total population who had received one or two vaccine doses were available for the

periods up until 11th April 2021 (for the Isle of Man [28]) and 21st April 2021 (for Israel

[29]).

To explore how the risk of outbreaks is likely to change in future, we projected the

vaccine rollout forwards beyond these dates in the following way. We considered the

total population size of the location under consideration (denoted N), as well as the

numbers of individuals ($N_1(t)$ and $N_2(t)$) vaccinated with one or two doses, so that

$V_1(t) = N_1(t)/N$ and $V_2(t) = N_2(t)/N$. We assumed that a constant number of vaccine

doses are available each day in future (denoted D), and that there is a target period of τ

days between each vaccine dose. On any day in future, each available dose is assigned

to an individual who has been vaccinated with their first dose at least τ days ago, with

remaining doses then assigned to unvaccinated individuals. Resulting values of $N_1(t)$

and $N_2(t)$ were then converted to corresponding values of $V_1(t)$ and $V_2(t)$. To reflect the

fact that vaccine uptake is imperfect, we assumed that a maximum proportion v of the

population can ever be vaccinated. Consequently, once the vaccination programme is

complete, then $\Lambda(t) = \eta_2 v$. Since there is uncertainty in the vaccine uptake going

forwards, we conducted supplementary analyses in which we considered a range of

different values of v. Values of the model parameters used in the analyses in the main

text for the Isle of Man and Israel are shown in Table 1.

<u>Outbreak risk metrics</u>

We used four different metrics to assess the risk that an infected individual, introduced

into the population at time t, initiates an outbreak driven by sustained local

transmission. The values of each of these metrics vary temporally. An overview of these

metrics is provided here; additional details are available in the Supplementary

Information.

The first metric we considered is the *Instantaneous Outbreak Risk (IOR)*. This quantity

represents the expression shown in equation (1), with $R = R_V(t)$ and $I_0 = 1$. The IOR

reflects the risk of an outbreak occurring starting from a single infected individual at time

t, but under the assumption that the vaccine rollout does not continue after time t so

that pathogen transmissibility is unchanged. While the IOR straightforward to calculate,

it does not reflect changing population immunity due to vaccination over the initial phase

of the potential outbreak. This standard metric is often used to assess the risk of

outbreaks in scenarios where pathogen transmissibility does not vary temporally [21–

24,30–32].

The second metric is the *Case Outbreak Risk (COR)*. The COR is an extension of the

IOR, accounting for changes in population susceptibility due to vaccination over the

initial phase of the potential outbreak. The COR has previously been used to assess

outbreak risks using branching processes for models in which pathogen transmission

varies periodically [30,33–35]. Its calculation involves solving the differential equation

$$\frac{dq(t)}{dt} = \beta(1 - \Lambda(t))q(t)\big(1 - q(t)\big) + \mu(q(t) - 1). \qquad (3)$$

The COR at time t is then given by $1 - q(t)$. Further details, including the derivation of

equation (3), are provided in the Supplementary Information.

The third metric we considered is the *Simulated Outbreak Risk (SOR)*. The SOR

involves repeated simulation of the branching process model, using the direct version of

the Gillespie stochastic simulation algorithm [36] adapted to account for temporally

varying pathogen transmissibility. Simulations were run starting with a single infected

individual introduced into the population at time t. The SOR then corresponds to the

proportion of simulations in which a local outbreak occurs; an outbreak is said to occur if

the total number of individuals infected simultaneously exceeds a pre-defined threshold

value, M. In our analyses, we set $M = 100$.

Finally, we consider the *Numerical Outbreak Risk (NOR)*. The NOR is analogous to the

SOR, but with the advantage that it does not require large numbers of model

simulations to be run. The NOR, therefore, also represents the risk that a single infected

individual introduced into the population at time t initiates an outbreak in which at least

$M = 100$ individuals are ever infected simultaneously.

Table 1: Default parameter values used in our analyses.

Parameter	Description	Value	Source
β	Transmission rate parameter	Set so that $R_0 = \frac{\beta}{\mu}$ takes a prescribed value	Two scenarios were considered, with median R_0 values of 3 (sim. to original SARS-CoV-2 variant [37]) and 5 (sim. to novel variant B.1.1.7 [20])
$1/\mu$	Duration of infectiousness	5 days	[38]
α	Delay between a vaccine dose being administered and being effective	14 days	[39]
η_1	Multiplicative reduction in susceptibility of an individual vaccinated with a single effective dose (compared to an unvaccinated host)	0.6	[17]
η_2	Multiplicative reduction in susceptibility of an individual vaccinated with two effective doses (compared to an unvaccinated host)	0.85	[17]
ν	Vaccine uptake	0.8 (Isle of Man) and 0.7 (Israel). Other values are considered in the Supplementary Information	[40]
N	Total population size	85,400 (Isle of Man) and 8,772,800 (Israel)	[41]
D	Number of vaccine doses available each day (in future projections)	1,000 (Isle of Man) and 56,000 (Israel)	Average number of doses administered each day in the previous 30 days (up to 11 April 2021 for Isle of

			Man [28] and 21 April 2021 for Israel [29])
τ	Target period between vaccine doses (in future projections)	84 days (Isle of Man) and 21 days (Israel)	[42,43]

3. RESULTS

As described in the Methods, we first generated projections of the number of vaccinated

individuals in future for the Isle of Man (Fig 2a) and Israel (Fig 2d), based on past

vaccination data in those locations. To explore the impact of vaccination on virus

transmission, we calculated the time-dependent reproduction number ($R_V(t)$; equation

(2)) throughout the vaccination campaign. We considered two different scenarios. In the

first, we set the median value of R_0 (i.e., the reproduction number in the absence of

vaccination) equal to 3, as was the situation early in the COVID-19 pandemic (Fig 2b,e).

In the second scenario, we set the median value of R_0 equal to 5 (Fig 2c,f) to reflect the

fact that currently circulating SARS-CoV-2 variants are more transmissible than the

original virus [20]. This second scenario is therefore likely to be a more realistic

reflection of the current and future risk.

Figure 2. Effect of vaccination on population susceptibility. (a) The proportion of the population of the Isle

of Man who are unvaccinated $(1 - V_1(t) - V_2(t))$, vaccinated with a single dose $(V_1(t))$ and vaccinated

with two doses $(V_2(t))$. The period in which vaccination data were available is shown in white, and the

period in which vaccination data were projected is shown in purple. (b) The time-dependent reproduction

number $(R_V(t))$ corresponding to the vaccination data in panel a, starting from a median initial value of

$R_V(0) = R_0 = 3$. To account for uncertainty in the value of R_0, a normal distribution was assumed about

the median value of R_0 with variance $\sigma^2 = 0.25$, which is reflective of the range of R_0 values estimated

early in the COVID-19 pandemic [37]. (c) Analogous to panel b but starting from a median initial value of

$R_V(0) = R_0 = 5$. (d)-(f) Analogous to panels a-c but using vaccination data for Israel. In all panels, $t = 0$

days corresponds to 18th December 2020. Ticks on the x-axes refer to the starts of the months labelled.

Parameter values are shown in Table 1.

We then calculated the values of the four different outbreak risk metrics throughout the

period considered (18th December 2020 to 20th August 2021) based on these

vaccination projections (Fig 3). This involves a scenario in which NPIs are removed

entirely, so that $R_V(t)$ is not reduced by interventions other than vaccination. These

metrics then reflect the risk that a single case first entering into the population at the

date of introduction shown initiates an outbreak driven by sustained local transmission,

given that no NPIs are in place. For each metric, and each time during the vaccination

programme, we calculated the outbreak risk by integrating over the full distribution for

$R_V(t)$ shown in Fig 2. The resulting outbreak risk therefore represents a point estimate

of the risk accounting for uncertainty in pathogen transmissibility.

The IOR represents the probability of sustained local transmission based only on the

value of $R_V(t)$ at the precise instance that the virus is introduced into the population.

When an introduction occurs while a vaccine is being deployed, there is a background

of decreasing population susceptibility, and so $R_V(t)$ may in fact decrease over the

initial stages of a potential outbreak. For that reason, it is unsurprising that the IOR

sometimes overestimates the outbreak risk compared to the other risk metrics (see e.g.

black lines in Fig 3a,c – and see Discussion).

In contrast, we found close agreement between the COR, SOR and NOR. Due to the

high assumed vaccine uptake in the Isle of Man, the outbreak risk at the end of the

vaccination programme there was calculated to be lower than when the vaccine rollout

was completed in Israel (although we also considered supplementary analyses with

different assumed vaccine uptake values – Fig S1). In the first scenario that we

considered (median $R_0 = 3$), which is representative of the transmissibility of the original

SARS-CoV-2 virus, the outbreak risk was projected to be low following the vaccination

programme in the Isle of Man.

However, when the virus was assumed to be more transmissible (median $R_0 = 5$), as is

the case for newly emerged variants of concern such as B.1.1.7, the outbreak risk was

found to be substantial even following the projected end of the vaccination campaigns in

both the Isle of Man and Israel. For example, when the assumed vaccine uptake values

of $v = 0.8$ and $v = 0.7$ had been achieved in the Isle of Man and Israel, respectively, the

NOR took values of 0.373 (95% credible interval [0.223,0.477] calculating using the

95% credible interval for $R_V(t)$ at the end of the vaccination rollout) and 0.506

([0.387,0.588]) in those locations.

Figure 3. The risk that an infectious case introduced at each stage of the vaccination campaign initiates

an outbreak, if travel restrictions and other NPIs are removed. (a) The outbreak risk assessed using the

four metrics (IOR – black; COR – blue dashed; SOR – green dots; NOR – red), based on vaccination

data from the Isle of Man and assuming $R_0 = 3$, as in Fig 2b. The period in which vaccination data were

available is shown in white, and the period in which vaccination data were projected is shown in purple.

(b) Analogous to panel b but with $R_0 = 5$ (see Fig 2c). (c) Analogous to panel a but using vaccination

data for Israel (see Fig 2e). (d). Analogous to panel a but using vaccination data for Israel with $R_0 = 5$

(see Fig 2f). Ticks on the x-axes refer to the starts of the months labelled. Parameter values are shown in

Table 1.

4. DISCUSSION

As vaccines are administered in countries around the world, attention has turned to the possibility that transmission will soon be reduced to the extent that travel restrictions and other NPIs can be relaxed. Here, we have investigated the impact of removing NPIs on the risk of outbreaks occurring in locations with low prevalence and a significant proportion of the population vaccinated. We used four metrics to quantify the risk that a case introduced at any stage in the vaccination rollout leads to an outbreak driven by local transmission, in a scenario in which NPIs are removed. We calculated temporal changes in the values of these metrics in the context of vaccination in the Isle of Man and in Israel, two locations with low prevalence and vaccination campaigns that have progressed quickly.

We found that vaccination is leading to a substantial drop in the potential for virus transmission in both the Isle of Man and Israel, as indicated by a decreasing value of the time-dependent reproduction number, $R_V(t)$ (Fig 2). However, even when the vaccine rollout is completed, a combination of vaccines not preventing transmission entirely, incomplete vaccine uptake and the emergence of novel SARS-CoV-2 variants suggests that the risk of outbreaks initiated by infected individuals arriving from elsewhere will not be eliminated when NPIs are removed (Fig 3). This conclusion remained true unless the vaccine uptake was very high (Fig S1). This suggests that, when NPIs such as travel restrictions are relaxed, it will still be advisable to be aware of the potential for local transmission. Ensuring that case numbers are reduced elsewhere

(i.e., in locations that imported cases might travel from) will reduce the risk of

importations, and strategies should be considered to suppress local outbreaks quickly if

importations occur.

One potential use of our modelling framework by policy-makers is to identify the dates

on which travel restrictions can be relaxed, based on a maximum acceptable outbreak

risk. As an example, if the maximum acceptable value of the NOR is 0.4, then our

analysis with $R_0 = 5$ suggests that travel restrictions can be lifted on the Isle of Man at

the end of July 2021 (Fig 3b; the first date on which the NOR falls below 0.4 is 29th July

2021). However, as described above, since the risk of local transmission following

introductions remains, it will be necessary to continue to monitor inbound passengers in

low prevalence settings to identify infected individuals, even once vaccine programmes

are complete.

Our modelling approach for assessing outbreak risks was motivated by studies in which

the potential for pathogen transmission varies periodically [30,33–35,44–47], due, for

example, to seasonal changes in weather conditions that affect transmission. In that

context, Carmona and Gandon [33] describe a "winter is coming effect", in which the

risk of an outbreak is lower than current environmental conditions suggest if conditions

become less favourable for transmission in the near future. In the terminology used in

our manuscript, if current environmental conditions promote pathogen transmission,

then the IOR is expected to be high. This is because the IOR reflects the outbreak risk

based on the conditions at the precise instance when the virus is introduced into the

population. However, if environmental conditions are expected to become less

favourable for transmission in the near future, then the values of the other risk metrics

are lower than the IOR, since those metrics account for changes in transmissibility over

the initial phase of the potential outbreak. Although in general we found a close

agreement between the four metrics that we considered, a background of decreasing

population susceptibility can lead to a similar effect in which the IOR is larger than the

COR, SOR or NOR (e.g. Fig 3a,c).

In this study, we used a simple branching process model to investigate the risk of

outbreaks when NPIs are removed during a vaccination programme. This involved

considering whether introduced cases are likely to lead to sustained local transmission

or instead fade out without causing an outbreak. We made the standard branching

process modelling assumption that population immunity is unaffected by infections in

the earliest stages of potential outbreaks [21–24,48,49]. In other words, infection-

acquired immunity following the arrival of the pathogen in the host population is not

considered. While this is reasonable when case numbers are low in the initial stages of

potential outbreaks, a more detailed model is needed to explore other quantities, such

as the eventual size of outbreaks. Following a vaccination programme, outbreaks are

likely to be smaller than those that occur before vaccines are widely administered.

Another simplification of our model is that we only accounted for changes in population

susceptibility due to the vaccine rollout. We did not account for prior immunity of some

members of the population due to previous exposures to the virus. At the time of writing

(1st May 2021), there have been 1,154 confirmed cases in the Isle of Man and 838,000

confirmed cases in Israel. Since these case numbers correspond to a relatively small

proportion of the host population (representing 1.35% and 9.55% of the population in

the Isle of Man and Israel, respectively), we do not expect this assumption to affect our

key findings. Furthermore, immunity is likely to wane over time [50,51], reducing the

effect of previous exposures on the outbreak risk. To test the potential impact of

infection-induced immunity arising from cases occurring before May 2021, we also

conducted a supplementary analysis in which the value of R_0 is reduced by 1.35% in the

Isle of Man and 9.55% in Israel, and we found qualitatively similar results (Fig S2): even

in this "best case" scenario, there is still a risk of outbreaks due to imported cases once

the vaccination programmes are completed. Importantly, in other countries in which

higher numbers of cases have occurred, prior immunity may play a larger role in

reducing the risk of outbreaks compared to the low prevalence settings considered

here. Understanding the extent of this effect, based on the rate at which immunity

wanes, is an important target for further study.

In this research, we assumed that vaccines reduce transmission by lowering the

probability that a vaccinated host becomes infected compared to an unvaccinated host.

In reality, vaccination can reduce the probability of infection as assumed here [52],

reduce the risk of onwards transmission following infection [7], reduce the risk of severe

disease developing, or a combination of these effects [53]. In principle, it would be

possible to develop a more complex model that accounts for each of these effects. It

would also be possible to include other factors affecting transmission and vaccination,

for example the impact of population-structure on both vaccine efficacy [54] and

transmission [55,56], or the possibility that individuals' behaviour may be different

following the pandemic compared to beforehand, even when NPIs and travel restrictions

are removed. For precise quantitative outbreak risk predictions to be made, it may be

necessary to estimate R_0 in different locations. The value of R_0 might be expected to

differ between countries, and inference of pathogen transmissibility in low prevalence

settings where only limited case notification data are available is an important challenge

[57,58].

Despite its simplicity, our modelling approach has demonstrated the general principle

that, even following complete vaccination programmes in low prevalence settings, the

risk of outbreaks remains when NPIs are removed. Our intention is not to argue that

travel restrictions and other NPIs should not be relaxed once vaccination programmes

are sufficiently advanced, but rather that measures should be taken to ensure that any

clusters of cases are suppressed quickly if they arise. A local outbreak requires two

steps: first, the virus must be imported from elsewhere; second, local transmission must

occur. The first step emphasises the need for a global approach to minimising

transmission, since large case numbers at a potential source location translates into a

higher importation risk. The second step emphasises the need to ensure that, while

vaccination acts to reduce transmission substantially, continued surveillance of inbound

passengers for infection, combined with isolation and testing of contacts of detected

infected individuals, is important when travel restrictions and other NPIs are relaxed.

These measures are necessary, since only once the global prevalence of SARS-CoV-2

infections is reduced substantially can the risk of outbreaks in low prevalence settings

be eliminated.

COMPETING INTERESTS

We have no competing interests.

DATA ACCESSIBILITY

All data required to reproduce the results presented here are available at

https://github.com/robin-thompson/Outbreaks_Low_Prevalence_Settings/. Raw data are

also shown in Figs 2a and 2d. No restrictions exist on data availability.

CODE AVAILABILITY STATEMENT

All code required to reproduce the results presented here are available at

https://github.com/robin-thompson/Outbreaks_Low_Prevalence_Settings/, along with

relevant documentation.

AUTHORS' CONTRIBUTIONS

Conceptualization: RS-P, RNT, LD; Methodology: RS-P, RNT; Investigation: RS-P;

Supervision: RNT, HMB; Writing – original draft: RNT, RS-P; Writing – review and editing:

All authors.

FUNDING

RS-P is supported by the EPSRC through the Centre for Doctoral Training in Industrially

Focussed Mathematical Modelling at the University of Oxford (grant EP/L015803/1), in

collaboration with Biosensors Beyond Borders Ltd. LD was supported by the MRC

through the COVID-19 Rapid Response Rolling Call (grant MR/V009761/1) and by UKRI

through the JUNIPER modelling consortium (grant MR/V038613/1). The funders had no

role in study design, data collection and analysis, preparation of the manuscript or the

decision to publish.

ACKNOWLEDGEMENTS

We thank members of the Wolfson Centre for Mathematical Biology (University of Oxford)

and the Zeeman Institute for Systems Biology and Infectious Disease Epidemiology

Research (University of Warwick) for helpful discussions about this work.

456   **REFERENCES**

1.   Liu Y, Morgenstern C, Kelly J, Lowe R, Jit M. The impact of non-pharmaceutical

interventions on SARS-CoV-2 transmission across 130 countries and territories.

BMC Med. 2021;19: 40.

2.   Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and

severity in China outside Hubei after control measures, and second-wave

scenario planning: a modelling impact assessment. Lancet. 2020;395: 1382–

1393.

3.   Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact

assessment of non-pharmaceutical interventions against coronavirus disease

2019 and influenza in Hong Kong: an observational study. Lancet Public Heal.

2020;4: 397–404.

4.   Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The

effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-

19) outbreak. Science (80-). 2020;368: 395–400.

5.   Daon Y, Thompson RN, Obolski U. Estimating COVID-19 outbreak risk through

air travel. J Travel Med. 2020;27: taaa093.

6.   Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of

control strategies to reduce social mixing on outcomes of the COVID-19 epidemic

in Wuhan, China: a modelling study. Lancet Public Heal. 2020;5: e261–e270.

7.   Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Impact of

vaccination on household transmission of SARS-COV-2 in England. medRxiv.

2021.

8.   Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics

after a national immunization program in Israel. Nat Med. 2021.

9.   Shah AS, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of

vaccination on transmission of COVID-19: an observational study in healthcare

workers and their households. medRxiv. 2021.

10.   Richterman A, Meyerowitz EA, Cevik M. Indirect protection by reducing

transmission: Ending the pandemic with SARS-CoV-2 vaccination. Open Forum

Infect Dis. 2021; ofab259.

11.   Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety

and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383.

12. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-

CoV-2: an interim analysis of four randomised controlled trials in Brazil, South

Africa, and the UK. Lancet. 2021;397.

13. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and

Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384.

14. Baker MG, Wilson N, Blakely T. Elimination could be the optimal response

strategy for covid-19 and other emerging pandemic diseases. BMJ. 2020;371.

15. Huang QS, Wood T, Jelley L, Jennings T, Jefferies S, Daniells K, et al. Impact of

the COVID-19 nonpharmaceutical interventions on influenza and other respiratory

viral infections in New Zealand. Nat Commun. 2021;12.

16. Baker MG, Wilson N, Anglemyer A. Successful elimination of Covid-19

transmission in New Zealand. N Engl J Med. 2020;383.

17. Keeling MJ, Moore S, Dyson L, Tildesley MJ, Hill EM. Road map scenarios and

sensitivity. 2021. Available:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/atta

chment_data/file/975911/S1184_SPI-

M_University_of_Warwick_Road_Map_Scenarios_and_Sensitivity.pdf

18. Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and non-

pharmaceutical interventions for COVID-19: a mathematical modelling study.

Lancet Infect Dis. 2021;S1473-3099: 00143–2.

19. Razai MS, Osama T, McKechnie DGJ, Majeed A. Covid-19 vaccine hesitancy

among ethnic minority groups. BMJ. 2021.

20. Davies N, Abbott S, Barnard R, Jarvis C, Kucharski A, Munday J, et al. Estimated

transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science

(80-). 2021.

21. Althaus CL, Low N, Musa EO, Shuaib F, Gsteiger. Ebola virus disease outbreak

in Nigeria: Transmission dynamics and rapid control. Epidemics. 2015;11: 80–84.

22. Thompson RN, Gilligan CA, Cunniffe NJ. Detecting presymptomatic infection is

necessary to forecast major epidemics in the earliest stages of infectious disease

outbreaks. PLoS Comput Biol. 2016;12: e1004836.

23. Merler S, Ajelli M, Fumanelli L, Parlamento S, y Piontti AP, Dean NE, et al.

Containing Ebola at the source with ring vaccination. PLoS Negl Trop Dis.

2016;10: e0005093.

24. Thompson RN. Novel coronavirus outbreak in Wuhan, China, 2020: Intense

surveillance is vital for preventing sustained transmission in new locations. J Clin

Med. 2020;9: 498.

25. Fraser C. Estimating individual and household reproduction numbers in an

emerging epidemic. PLoS One. 2007;2: e758.

26. White LF, Moser CB, Thompson RN, Pagano M. Statistical estimation of the

reproductive number from case notification data. Am J Epidemiol. 2020; kwaa211.

27. Thompson RN, Stockwin JE, Gaalen RD Van, Polonsky JA, Kamvar ZN, Demarsh

PA, et al. Improved inference of time-varying reproduction numbers during

infectious disease outbreaks. Epidemics. 2019;19: 100356.

28. Isle of Man Government. COVID-19 Vaccination Programme. 2021 [cited 15 Apr

2021]. Available: https://covid19.gov.im/about-coronavirus/open-data-downloads/

29.   Our World in Data. Coronavirus (COVID-19) vaccinations. 2021 [cited 23 Apr

2021]. Available: https://ourworldindata.org/covid-vaccinations

30.   Bromiley J, Hart WS, Iwami S, Thompson RN. Assessing the threat from

emerging infectious diseases in seasonally varying environments. preprint. 2021.

31.   Keeling MJ, Rohani P. Modeling infectious diseases in humans and animals.

Princeton University Press; 2008.

32.   Thompson RN, Gilligan CA, Cunniffe NJ. Will an outbreak exceed available

resources for control? Estimating the risk from invading pathogens using practical

definitions of a severe epidemic. J R Soc Interface. 2020;17: 20200690.

33.   Carmona P, Gandon S. Winter is coming: Pathogen emergence in seasonal

environments. PLoS Comput Biol. 2020;16: e1007954.

34.   Ball FG. The threshold behaviour of epidemic models. J Appl Probab. 1983;20:

227–241.

35.   Bacaër N, Ait Dads EH. On the probability of extinction in a periodic environment.

J Math Biol. 2014;68: 533–548.

36.   Gillespie DT. Exact stochastic simulation of coupled chemical reactions. J Phys

Chem. 1977;8: 2340–2361.

37.   Billah MA, Miah MM, Khan MN. Reproductive number of coronavirus: A

systematic review and meta-analysis based on global level evidence. PLoS One.

2020;15.

38.   Kucharski AJ, Klepac P, Conlan AJK, Kissler SM, Tang ML, Fry H, et al.

Effectiveness of isolation, testing, contact tracing, and physical distancing on

reducing transmission of SARS-CoV-2 in different settings: a mathematical

modelling study. Lancet Infect Dis. 2020;20.

39. Centers for Disease Control and Prevention. Interim public health

recommendations for fully vaccinated people. 2021.

40. Sallam M. Covid-19 vaccine hesitancy worldwide: A concise systematic review of

vaccine acceptance rates. Vaccines. 2021.

41. Worldometer. Current world population. 2021 [cited 21 Apr 2021]. Available:

https://www.worldometers.info/world-population/

42. Isle of Man Government. Frequently asked questions about the vaccine. 2021.

43. Wise J. Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel,

shows peer reviewed study. BMJ. 2021;372.

44. Klein B, MacDonald PDM. The multitype continuous-time Markov branching

process in a periodic environment. Adv Appl Probab. 1980;12: 81–93.

45. Jagers P, Nerman O. Branching processes in periodically varying environment.

Ann Probab. 1985;13: 254–268.

46. Nipa KF, Allen LJS. Disease emergence in multi-patch stochastic epidemic

models with demographic and seasonal variability. Bull Math Biol. 2020;82: 152.

47. Bacaër N, Ed-Darraz A. On linear birth-and-death processes in a random

environment. J Math Biol. 2014;69: 73–90.

48. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility

of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet

Glob Heal. 2020;8: E488-496.

49. Lovell-Read FA, Funk S, Obolski U, Donnelly CA, Thompson RN. Interventions

targeting non-symptomatic cases can be important to prevent local outbreaks:

SARS-CoV-2 as a case study. J R Soc Interface. 2021;18: 20201014.

50.   Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd

immunity to SARS-CoV-2 infection by mass vaccination. The Lancet. 2020. p.

10263.

51.   Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the

transmission dynamics of SARS-CoV-2 through the postpandemic period.

Science (80-). 2020;368: 860–868.

52.   Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al.

Impact of vaccination on SARS-CoV-2 cases in the community: a population-

based study using the UK's COVID-19 Infection Survey. medRxiv.

53.   Gog JR, Hill EM, Danon L, Thompson RN. Vaccine escape in heterogeneous

populations: insights for SARS-CoV-2 from a simple model. medRxiv. 2021.

54.   Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-

informed COVID-19 vaccine prioritization strategies by age and serostatus.

Science (80-). 2021;371.

55.   Britton T, Ball F, Trapman P. A mathematical model reveals the influence of

population heterogeneity on herd immunity to SARS-CoV-2. Science (80-). 2020.

56.   Davies NG, Klepac P, Liu Y, Prem K, Jit M, CMMID COVID-19 Working Group, et

al. Age-dependent effects in the transmission and control of COVID-19 epidemics.

Nat Med. 2020.

57.   Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, et

al. Key questions for modelling COVID-19 exit strategies. Proc R Soc B Biol Sci.

2020;287: 20201405.

58.   Sturrock HJ, Bennett AF, Midekisa A, Gosling RD, Gething PW, Greenhouse B.

Mapping malaria risk in low transmission settings: challenges and opportunities.

Trends Parasitol. 2016;32: 635–645.

608